,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['trastuzumab', 'trastuzumab deruxtecan', 'mbc', 'meru']
trastuzumab deruxtecan is new standard of care for her2-low mbc via . while most oncs who prev rx tdxd are not surprised, still so impressed! best said, these are modular drugs. homerun here, and more to come #adc #asco22
Medical oncologist. Breast cancer specialist. New Yorker. Closet DIY enthusiast. Tweets my views alone.